3 Red-Hot Stocks That Are Still Dirt Cheap
BioNTech and Pfizer look for the vaccine to rake in sales of around $26 billion this year. BioNTech's shares are trading at a seeming bargain because investors aren't sure how much recurring revenue the company will be able to count on after 2022. If booster doses are needed going forward, BioNTech's future sales could be massive for a long time to come.